Brazil Kidney Cancer Therapeutics Market Analysis

Brazil Kidney Cancer Therapeutics Market Analysis Executive Summary

Brazil's Kidney Cancer Therapeutics Market is at around $157.25 Mn in 2023 and is projected to reach $234.27 Mn in 2030, exhibiting a CAGR of 5.86% during the forecast period.

Kidney cancer is characterized by the development of malignant tumors in the kidneys. The elderly, usually in their 50s to 70s, are the main victims of renal cell carcinoma. Typical symptoms include blood in the urine, tiredness, pain in the back or flanks, an abdominal bulge or lump, lack of appetite, and accidental weight loss. Although the precise origin of kidney cancer is frequently unknown, risk factors like smoking, obesity, high blood pressure, and family history might raise the disease's chance of occurring.  The most popular form of treatment for chronic renal illness is kidney transplantation.

Kidney cancer is the 13th most common cancer in Brazil with nearly 12,000 new cases reported in 2020. Renal cell carcinomas (RCCs) comprise 2-3% of all adult cancer cases and 80–85% of cases of kidney cancer. Male patients outweigh female patients by a ratio of 3:2. Numerous known risk factors include obesity, hypertension, smoking, and acquired renal cystic disease. 1-3% of cases are inherited, although the majority are random. The market is growing due to an increase in the Geriatric Population, a Rise in Lifestyle disorders, and a Growing Pipeline of Novel Therapies. However Regulatory barriers, Side effects, and High cost of treatment restrict the growth and potential of the market.

Pfizer Inc. (U.S.), AstraZeneca (U.K.), Bristol-Myers Squibb Company (U.S.) are key players in the Brazil Kidney Cancer Therapeutics Market.

Market Dynamics

Market Growth Drivers

Increase in Geriatric Population: In Brazil, the percentage of the old population has increased dramatically since 1950. As an example, the number of elderly people in 1950 was just approximately 2.6 Mn, or 4.9% of the total population. The number of senior people reached 30.1 Mn in 2020 or roughly 14.3% of the total population. In addition, projections indicate that the number of elderly individuals would rise to 73.4 Mn by 2060. Given that the elderly population is more prone to cancer, this is expected to propel the market for cancer therapy.

Rise in Lifestyle Disorders: In Brazil, more individuals are leading sedentary lifestyles as a result of rising disposable income and urbanization. Because of this, the population is becoming more susceptible to lifestyle disorders like obesity and hypertension. As an example, the percentage of people who are obese rose from 12.2% in 2003 to approximately 22.1% in 2021. Furthermore, the percentage of overweight people in the population rose from 43.3% in 2003 to 61.7% in 2019. In addition, it is projected that 40.7% of Brazilians have high blood pressure. Given that obesity and hypertension are two of the main risk factors for cancer, this is what is driving demand.

Growing Pipeline of Novel Therapies: A significant breakthrough in oncology has been made possible by the pharmaceutical industry's investment in the creation of innovative treatments for kidney cancer. Targeted therapies, which attempt to interfere with certain molecular processes involved in the development and spread of cancer, are one area in which this dedication is very clear. With fewer side effects than conventional chemotherapy, targeted therapies have the potential to be more effective because they specifically target certain pathways. Additionally, a novel strategy for treating kidney cancer is immunotherapies, which use the body's immune system to identify and destroy cancer cells.

Market Restraints

Regulatory Barrier: New kidney cancer treatments and diagnostics must receive regulatory approval through a complex process that includes demanding clinical trials and regulatory restrictions. By carefully examining the results of several preclinical and clinical investigations, these regulatory agencies assess the safety, effectiveness, and caliber of investigational items, making sure they fulfill the requirements for patient use. Treatments for kidney cancer usually undergo multiphase clinical trials: Phase I studies to test safety, Phase II trials to assess efficacy in a broader patient group, and Phase III trials to confirm efficacy and track side effects.

Side effects: The side effects of kidney cancer drugs can vary depending on the specific treatment chosen. Kidney cancer is treated with a number of typical side effects of different therapeutic classes, such as immunotherapies and targeted treatments. The side effects of targeted treatments, like sunitinib, pazopanib, and cabozantinib, can include thinning hair, constipation, diarrhea, or exhaustion; vomiting; nausea; increased blood pressure; hand-foot syndrome; and problems with the skin, such as rash, dryness, or discoloration; and changes in blood pressure.

High cost of treatment: One key issue that may hinder market expansion is the high cost of cancer therapy. The yearly mean cost per patient for cancer therapy in Brazil was $9,572.3, with the range being $5,782.1 for breast cancer and $16,656 for cervical cancer, according to data from the US National Institute of Health and Health (NIH). Given that the average per capita income of the nation is only expected to be $14,550 in 2020, this may render high-quality cancer therapy unaffordable to the great majority of the population. Not only that, but Brazil offers free public healthcare; nevertheless, due to overcrowding in the facilities, wait times for medical services can be very lengthy.

Regulatory Landscape and Reimbursement Scenario

The Brazilian Health Regulatory Agency (ANVISA), which oversees healthcare goods and services from clinical trial authorization to post-marketing surveillance, is responsible for granting marketing authorization (MA) in Brazil. The 10-year MA by Anvisa certifies that medications are high-quality, safe, and effective. Companies must also apply for maximum pricing clearance from the Drug Market Regulatory Chamber (CMED) in order to be permitted to enter the Brazilian market.

All citizens and visitors, including those without legal status, have free and full access to a range of services, including hospital, mental health, outpatient specialty, primary, and prescription drug coverage. There is no need for an application procedure. When it comes to medical treatments, there is no cost-sharing. Approximately 25% of Brazilians, primarily those from middle-class and upper-class backgrounds, possess private health insurance in order to avoid obstacles when seeking medical attention. Costs associated with purchasing health-related items and private health insurance are deductible from taxes.

Competitive Landscape

Here are some of the major key players in the Brazil Kidney Cancer Therapeutics Market:

Key Players

• Abbott (U.S.)
• Abbott Laboratories
• Amgen Inc.6.1.3 Bayer AG
• Bristol-Myers Squibb
• F. Hoffmann-La Roche
• Merck
• Novartis International AG
• Pfizer Inc
• Sanofi
• AstraZeneca